gamithromycin profile

gamithromycin: an antibiotic used in cattle [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

gamithromycin : A macrolide antibiotic with formula C40H76N2O12. It is used for the treatment of of bovine respiratory disease caused by Mannheimia haemolytica, Pasteurella multocida, Histophilus somni and Mycoplasma bovis in beef and non-lactating dairy cattle. The compound is also licensed in Europe for the treatment of footrot in sheep caused by Dichelobacter nodosus and Fusobacterium nodosus. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID Source	ID
PubMed CID	59364992
CHEMBL ID	2107342
CHEBI ID	195437
MeSH ID	M0550265

Synonyms (46)

Synonym
145435-72-9
zactran
gamithromycinum
ml-1,709,460
(2r,3s,4r,5s,8r,10r,11r,12s,13s,14r)-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexamethyl-15-oxo-7-propyl-11-{[3,4,6-trideoxy-3-(dimethylamino)-beta-d-xylo-hexopyranosyl]oxy}-1-oxa-7-azacyclopentadecan-13-yl 2,6-dideoxy-3-c-methyl-3-o-methyl-alpha-l-ribo-h
gamithromycin
(2r,3s,4r,5s,8r,10r,11r,12s,13s,14r)-13-[(2,6-dideoxy-3-c-methyl-3-o-methyl-alpha-l-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexamethyl-7-propyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-beta-d-xylo-hexopyranosyl]oxy]-1-oxa-7-azacyclop
ml-460
gamitromicina
ml-1709460
ml 1709460
CHEBI:195437
gamithromycin [usan:inn]
ze856183s0 ,
unii-ze856183s0
CHEMBL2107342
AKOS016007692
(2r,3s,4r,5s,8r,10r,11r,12s,13s,14r)-13-((2,6-dideoxy-3-c-methyl-3-o-methyl-.alpha.-l-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexamethyl-7-propyl-11-((3,4,6-trideoxy-3-(dimethylamino)-.beta.-d-xylo-hexopyranosyl)oxy)-1-oxa-7-azacy
gamithromycin [green book]
1-oxa-7-azacyclopentadecan-15-one, 13-((2,6-dideoxy-3-c-methyl-3-o-methyl-.alpha.-l-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexamethyl-7-propyl-11-((3,4,6-trideoxy-3-(dimethylamino)-.beta.-d-xylo-hexopyranosyl)oxy)-, (2r,3s,4r,5s,
gamithromycin [mi]
gamithromycin [usan]
gamithromycin [ema epar veterinary]
gamithromycin [inn]
S5328
CS-7858
AC-32611
EX-A1349
J-008105
(2r,3s,4r,5s,8r,10r,11r,12s,13s,14r)-11-(((2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2h-pyran-2-yl)oxy)-2-ethyl-3,4,10-trihydroxy-13-(((2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2h-pyran-2-yl)oxy)-3,5,8,10,12,14-hexamethyl-
HY-108365
DS-4441
DTXSID90904260 ,
mfcd09954125
DB11416
1-oxa-7-azacyclopentadecan-15-one,13-[(2,6-dideoxy-3-c-methyl-3-o-methyl-a-l-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexamethyl-7-propyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-b-d-xylo-hexopyranosyl]oxy]-,[2r-(2r,3s,4r,5s,8r*,1
C72760
(2r,3s,4r,5s,8r,10r,11r,12s,13s,14r)-11-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-2-ethyl-3,4,10-trihydroxy-13-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,8,10,12,14-hexamethyl-7-propyl-1-oxa-7-azacyclopentadeca
gamithromycin 100 microg/ml in methanol
(2r,3s,4r,5s,8r,10r,11r,12s,13s,14r)-13-[(2,6-dideoxy-3-cmethyl-3-o-methyl-a-l-ribo-hexopyranosyl)oxy]-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexamethyl-7-propyl-11-[[3,4,6-trideoxy-3-(dimethylamino)-b-d-xylo-hexopyranosyl]oxy]-1-oxa-7-azacyclopentadeca
A884620
dtxcid101333409
gamithromycin (ema epar veterinary)
1-oxa-7-azacyclopentadecan-15-one,13-((2,6-dideoy-3-c-methyl-3-o-methyl-alpha-l-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy 3,5,8,10,12,14-hexamethyl-7-propyl-11-((3,4,6-trideoxy-3-(dimethylamino)-beta-d-xylo-hexopyranosyl)oxy)-, ((2r, 3s,4r,5s,
(2r,3s,4r,5s,8r,10r,11r,12s,13s,14r)-13-((2,6-dideoxy-3-c-methyl-3-o-methyl-alpha-l-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,8,10,12,14-hexamethyl-7-propyl-11-((3,4,6-trideoxy-3-(dimethylamino)-beta-d-xylo-hexopyranosyl)oxy)-1-oxa-7-azacyclop
(2r,3s,4r,5s,8r,10r,11r,12s,13s,14r)-13-[(2,6-dideoxy-3-c-methyl-3-o-methyl-alpha-l-ribo-hexopyranosyl)

Excerpt	Reference	Relevance
"536 microgxh/mL, and mean elimination half-life (t(1/2)) was 44."	( Pharmacokinetics of gamithromycin in cattle with comparison of plasma and lung tissue concentrations and plasma antibacterial activity. Banav, N; Fischer, J; Huang, RA; Letendre, LT; Somerville, B, 2010)	0.36
"The aim of this study was to investigate the pharmacokinetic properties of gamithromycin in pigs after an intravenous (i."	( Pharmacokinetics of gamithromycin after intravenous and subcutaneous administration in pigs. Croubels, S; De Backer, P; De Baere, S; Meyer, E; Plessers, E; Watteyn, A; Wyns, H, 2014)	0.4
" Plasma peak concentration was 573 ± 168 ng/ml."	( Gamithromycin plasma and skin pharmacokinetics in sheep. Forbes, AB; Huang, RA; Kellermann, M; Rehbein, S, 2014)	0.4
" In synovial fluid, florfenicol pharmacokinetic parameters estimates were: mean Tmax 7 +/- 2 hours, mean t½ 64."	( Synovial fluid pharmacokinetics of tulathromycin, gamithromycin and florfenicol after a single subcutaneous dose in cattle. Coetzee, JF; Fajt, VR; Jones, ML; Rice, S; Washburn, KE, 2015)	0.42
" rhinotracheale infections are common in turkey flocks, the aim of this study was to determine the pharmacokinetic (PK) parameters of GAM in plasma, lung tissue, and pulmonary epithelial lining fluid (PELF) of turkeys and to correlate them with pharmacodynamic (PD) characteristics (PK/PD)."	( Pharmacokinetic and pharmacodynamic properties of gamithromycin in turkey poults with respect to Ornithobacterium rhinotracheale. Boyen, F; Croubels, S; De Backer, P; De Baere, S; Devreese, M; Haesebrouck, F; Plessers, E; Watteyn, A; Wyns, H, 2015)	0.42
"The objectives of this study were to determine (i) whether an association exists between individual pharmacokinetic parameters and treatment outcome when feeder cattle were diagnosed with bovine respiratory disease (BRD) and treated with gamithromycin (Zactran(®) ) at the label dose and (ii) whether there was a stronger association between treatment outcome and gamithromycin concentration in plasma or in the pulmonary epithelial lining fluid (PELF) effect compartment."	( Pharmacokinetics and pharmacodynamics of gamithromycin in pulmonary epithelial lining fluid in naturally occurring bovine respiratory disease in multisource commingled feedlot cattle. Apley, MD; Capik, SF; DeDonder, KD; Gehring, R; Harhay, DM; KuKanich, B; Li, M; Lubbers, BV; Riviere, JE; Tessman, RK; White, BJ, 2016)	0.43
" We provide evidence from a pharmacokinetic study in 10 warm-blooded healthy foals for intravenous bolus injection of gamithromycin diluted in distilled water to be a safe and well tolerated alternative."	( Pharmacokinetics and pulmonary distribution of gamithromycin after intravenous administration in foals. Berlin, S; Grube, M; Randow, T; Scheuch, E; Siegmund, W; Venner, M, 2017)	0.46
" The combination of rifampicin with the new, poorly metabolised gamithromycin, a long-acting analogue of azithromycin and tulathromycin with lower pharmacokinetic interaction potential, might be a suitable alternative."	( Intestinal and hepatic contributions to the pharmacokinetic interaction between gamithromycin and rifampicin after single-dose and multiple-dose administration in healthy foals. Berlin, S; Grube, M; Hasan, M; Oswald, S; Scheuch, E; Siegmund, W; Ullrich, A; Venner, M; Wallstabe, S; Wegner, D, 2018)	0.48
"To evaluate the pharmacokinetic interactions and pulmonary distribution of rifampicin and gamithromycin in healthy foals, and to investigate the cellular uptake of gamithromycin in vitro."	( Intestinal and hepatic contributions to the pharmacokinetic interaction between gamithromycin and rifampicin after single-dose and multiple-dose administration in healthy foals. Berlin, S; Grube, M; Hasan, M; Oswald, S; Scheuch, E; Siegmund, W; Ullrich, A; Venner, M; Wallstabe, S; Wegner, D, 2018)	0.48

Excerpt	Reference	Relevance
" Gamithromycin was well absorbed and fully bioavailable (97."	( Pharmacokinetics of gamithromycin in cattle with comparison of plasma and lung tissue concentrations and plasma antibacterial activity. Banav, N; Fischer, J; Huang, RA; Letendre, LT; Somerville, B, 2010)	0.36
" The absolute bioavailability was 102."	( Pharmacokinetics of gamithromycin after intravenous and subcutaneous administration in broiler chickens. Croubels, S; De Backer, P; De Baere, S; Plessers, E; Watteyn, A; Wyns, H, 2013)	0.39
"21 h and a high absolute bioavailability of 118%."	( Pharmacokinetics of gamithromycin after intravenous and subcutaneous administration in pigs. Croubels, S; De Backer, P; De Baere, S; Meyer, E; Plessers, E; Watteyn, A; Wyns, H, 2014)	0.4
" Blood samples were collected up to Day 10 to establish the plasma profile of gamithromycin, bioavailability and dose proportionality."	( Gamithromycin in swine: Pharmacokinetics and clinical evaluation against swine respiratory disease. Böhne, I; Dumont, P; Fraisse, F; Hamel, D; Huang, R; Kellermann, M; Letendre, L; Rauh, R; Rehbein, S; Richard-Mazet, A; Voisin, F, 2021)	0.62

Excerpt	Relevance	Reference
"5 times of the recommended dosage of 6 mg/kg of body weight."	( Pharmacokinetics of gamithromycin in cattle with comparison of plasma and lung tissue concentrations and plasma antibacterial activity. Banav, N; Fischer, J; Huang, RA; Letendre, LT; Somerville, B, 2010)	0.36
" Kids were randomly divided into two equal groups; the GM group received a single subcutaneous dose of GM at a dosage of 6 mg/kg and the MR group received MR intramuscularly at a dosage of 8 mg/kg as a single-dose."	( Comparing clinical effects of marbofloxacin and gamithromycin in goat kids with pneumonia. Batmaz, H; Kacar, Y; Mecitoglu, Z; Yilmaz, OE, 2018)	0.48

Role	Description
antibacterial drug	A drug used to treat or prevent bacterial infections.
protein synthesis inhibitor	A compound, usually an anti-bacterial agent or a toxin, which inhibits the synthesis of a protein.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
macrolide antibiotic	A macrocyclic lactone with a ring of twelve or more members which exhibits antibiotic activity.
monosaccharide derivative	A carbohydrate derivative that is formally obtained from a monosaccharide.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	33 (78.57)	24.3611
2020's	9 (21.43)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	13 (30.95%)	5.53%
Reviews	3 (7.14%)	6.00%
Case Studies	1 (2.38%)	4.05%
Observational	0 (0.00%)	0.25%
Other	25 (59.52%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
methanol Methanol: A colorless, flammable liquid used in the manufacture of FORMALDEHYDE and ACETIC ACID, in chemical synthesis, antifreeze, and as a solvent. Ingestion of methanol is toxic and may cause blindness.. primary alcohol : A primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it.. methanol : The primary alcohol that is the simplest aliphatic alcohol, comprising a methyl and an alcohol group.	2.25	1	0	alkyl alcohol; one-carbon compound; primary alcohol; volatile organic compound	amphiprotic solvent; Escherichia coli metabolite; fuel; human metabolite; mouse metabolite; Mycoplasma genitalium metabolite
amlodipine Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.. amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.	2.25	1	0	dihydropyridine; ethyl ester; methyl ester; monochlorobenzenes; primary amino compound	antihypertensive agent; calcium channel blocker; vasodilator agent
ketoprofen Ketoprofen: An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis.. ketoprofen : An oxo monocarboxylic acid that consists of propionic acid substituted by a 3-benzoylphenyl group at position 2.	4.47	2	2	benzophenones; oxo monocarboxylic acid	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-steroidal anti-inflammatory drug; xenobiotic
primaquine Primaquine: An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404). primaquine : An N-substituted diamine that is pentane-1,4-diamine substituted by a 6-methoxyquinolin-8-yl group at the N(4) position. It is a drug used in the treatment of malaria and Pneumocystis pneumonia.	2.25	1	0	aminoquinoline; aromatic ether; N-substituted diamine	antimalarial
4-butyrolactone 4-Butyrolactone: One of the FURANS with a carbonyl thereby forming a cyclic lactone. It is an endogenous compound made from gamma-aminobutyrate and is the precursor of gamma-hydroxybutyrate. It is also used as a pharmacological agent and solvent.. tetrahydrofuranone : Any oxolane having an oxo- substituent at any position on the tetrahydrofuran ring.. gamma-butyrolactone : A butan-4-olide that is tetrahydrofuran substituted by an oxo group at position 2.	3.16	1	0	butan-4-olide	metabolite; neurotoxin
aminoacetonitrile Aminoacetonitrile: Cyanomethylamine.	3.16	1	0
erythromycin Erythromycin: A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.. erythromycin : Any of several wide-spectrum macrolide antibiotics obtained from actinomycete Saccharopolyspora erythraea (formerly known as Streptomyces erythraeus).. erythromycin A : An erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively.	3.7	1	0	cyclic ketone; erythromycin
thiamphenicol [no description available]	2.11	1	0	monocarboxylic acid amide; sulfone	antimicrobial agent; immunosuppressive agent
methylformamide N-methylformamide : A member of the class of formamides having a N-methyl substituent.	2.25	1	0	formamides
pergolide Pergolide: A long-acting dopamine agonist which has been used to treat PARKINSON DISEASE and HYPERPROLACTINEMIA but withdrawn from some markets due to potential for HEART VALVE DISEASES.. pergolide : A diamine that is ergoline in which the beta-hydrogen at position 8 is replaced by a (methylthio)methyl group and the hydrogen attached to the piperidine nitrogen (position 6) is replaced by a propyl group. A dopamine D2 receptor agonist which also has D1 and D2 agonist properties, it is used as the mesylate salt in the management of Parkinson's disease, although it was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction.	3.16	1	0	diamine; methyl sulfide; organic heterotetracyclic compound	antiparkinson drug; dopamine agonist
marbofloxacin [no description available]	7.17	1	0	quinolines
enrofloxacin Enrofloxacin: A fluoroquinolone antibacterial and antimycoplasma agent that is used in veterinary practice.. enrofloxacin : A quinolinemonocarboxylic acid that is 1,4-dihydroquinoline-3-carboxylic acid substituted by an oxo group at position 4, a fluoro group at position 6, a cyclopropyl group at position 1 and a 4-ethylpiperazin-1-yl group at position 7. It is a veterinary antibacterial agent used for the treatment of pets.	3.7	1	0	cyclopropanes; N-alkylpiperazine; N-arylpiperazine; organofluorine compound; quinolinemonocarboxylic acid; quinolone	antibacterial agent; antimicrobial agent; antineoplastic agent
danofloxacin [no description available]	7.41	1	0	quinolines
florfenicol florfenicol: structure given in first source. florfenicol : A carboxamide that is the N-dichloroacetyl derivative of (1R,2S)-2-amino-3-fluoro-1-[4-(methanesulfonyl)phenyl]propan-1-ol. A synthetic veterinary antibiotic that is used for treatment of bovine respiratory disease and foot rot; also used in aquaculture.	7.11	1	0	organochlorine compound; organofluorine compound; secondary alcohol; secondary carboxamide; sulfone	antimicrobial agent
1-aminoindan [no description available]	2.25	1	0
firocoxib firocoxib: a COX-2 inhibitor; structure in first source. firocoxib : An enol ether that is the cyclopropylmethyl ether of 3-hydroxy-5,5-dimethyl-4-[4-(methylsulfonyl)phenyl]furan-2-one. A selective cyclooxygenase 2 inhibitor, it is used in veterinary medicine for the control of pain and inflammation associated with osteoarthritis in horses and dogs.	3.16	1	0	butenolide; cyclopropanes; enol ether; sulfone	antineoplastic agent; cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
zithromax Azithromycin: A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.. azithromycin : A macrolide antibiotic useful for the treatment of bacterial infections.	3.5	1	1	macrolide antibiotic	antibacterial drug; environmental contaminant; xenobiotic
lincomycin Lincomycin: An antibiotic produced by Streptomyces lincolnensis var. lincolnensis. It has been used in the treatment of staphylococcal, streptococcal, and Bacteroides fragilis infections.. lincomycin : A carbohydrate-containing antibiotic produced by the actinomyces Streptomyces lincolnensis.	3.7	1	0	carbohydrate-containing antibiotic; L-proline derivative; monocarboxylic acid amide; pyrrolidinecarboxamide; S-glycosyl compound	antimicrobial agent; bacterial metabolite
dinoprostone prostaglandin E2 : Prostaglandin F2alpha in which the hydroxy group at position 9 has been oxidised to the corresponding ketone. Prostaglandin E2 is the most common and most biologically potent of mammalian prostaglandins.	4.47	2	2	prostaglandins E	human metabolite; mouse metabolite; oxytocic
tulathromycin tulathromycin: structure in first source	7.19	7	4	aminoglycoside
tildipirosin 20,23-dipiperidinyl-mycaminosyl-tylonolide: a veterinary antibiotic	7.9	2	0
monepantel monepantel: Anthelmintic; effective gainst fourth stage gastro-intestinal nematode larvae infecting sheep. monepantel : A secondary carboxamide resulting from the formal condensation of the carboxy group of p-[(trifluoromethyl)sulfanyl]benzoic acid with the amino group of (2S)-2-amino-3-hydroxy-2-methylpropanenitrile in which the hydroxy group has been converted to the corresponding 5-cyano-2-(trifluoromethyl)phenyl ether. A broad-spectrum nematicide, it is used to control gastrointestinal roundworms in sheep and goats.	3.16	1	0	(trifluoromethyl)benzenes; aromatic ether; aryl sulfide; nitrile; secondary carboxamide	anthelminthic drug; nematicide
tilmicosin tilmicosin: semi-synthetic antibiotic. tilmicosin : A macrolide antibiotic with formula C46H80N2O13. It is used for the treatment of respiratory disease in cattle at high risk of developing bovine respiratory disease associated with Mannheimia haemolytica.	3.61	2	0
tylosin [no description available]	3.95	3	0
oxytetracycline, anhydrous Oxytetracycline: A TETRACYCLINE analog isolated from the actinomycete STREPTOMYCES RIMOSUS and used in a wide variety of clinical conditions.. oxytetracycline : A tetracycline used for treatment of infections caused by a variety of Gram positive and Gram negative microorganisms including Mycoplasma pneumoniae, Pasteurella pestis, Escherichia coli, Haemophilus influenzae (respiratory infections), and Diplococcus pneumoniae.	5.63	4	1
rifampin Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)	4.83	3	2	cyclic ketal; hydrazone; N-iminopiperazine; N-methylpiperazine; rifamycins; semisynthetic derivative; zwitterion	angiogenesis inhibitor; antiamoebic agent; antineoplastic agent; antitubercular agent; DNA synthesis inhibitor; EC 2.7.7.6 (RNA polymerase) inhibitor; Escherichia coli metabolite; geroprotector; leprostatic drug; neuroprotective agent; pregnane X receptor agonist; protein synthesis inhibitor

Condition	Relationship Strength	Studies	Trials
Abdominal Cramps [description not available]	2.41	1	0
Mastitis, Bovine INFLAMMATION of the UDDER in cows.	2.41	1	0
Bovine Diseases [description not available]	6.27	6	2
Foot Rot A disease of the horny parts and of the adjacent soft structures of the feet of cattle, swine, and sheep. It is usually caused by Corynebacterium pyogenes or Bacteroides nodosus (see DICHELOBACTER NODOSUS). It is also known as interdigital necrobacillosis. (From Black's Veterinary Dictionary, 18th ed)	5.14	3	1
Ovine Diseases [description not available]	5.34	4	1
Bacterial Disease [description not available]	3.64	1	1
Infections, Respiratory [description not available]	4.07	2	1
Swine Diseases Diseases of domestic swine and of the wild boar of the genus Sus.	4.83	3	2
Bacterial Infections Infections by bacteria, general or unspecified.	3.64	1	1
Respiratory Tract Infections Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases.	4.07	2	1
Pleuropneumonia, Contagious A pleuropneumonia of cattle and goats caused by species of MYCOPLASMA.	2.21	1	0
Mandibular Diseases Diseases involving the MANDIBLE.	2.25	1	0
Osteomyelitis INFLAMMATION of the bone as a result of infection. It may be caused by a variety of infectious agents, especially pyogenic (PUS - producing) BACTERIA.	7.25	1	0
Electrolytes Substances that dissociate into two or more ions, to some extent, in water. Solutions of electrolytes thus conduct an electric current and can be decomposed by it (ELECTROLYSIS). (Grant & Hackh's Chemical Dictionary, 5th ed)	2.25	1	0
Haemophilus Infections Infections with bacteria of the genus HAEMOPHILUS.	2.31	1	0
Infections, Pasteurella [description not available]	3.92	2	1
Bordetella Infections Infections with bacteria of the genus BORDETELLA.	2.31	1	0
Actinobacillus Infections Infections with bacteria of the genus ACTINOBACILLUS.	2.31	1	0
Equine Diseases [description not available]	3.92	2	1
Actinomycetales Infections Infections with bacteria of the order ACTINOMYCETALES.	3.92	2	1
Bovine Respiratory Disease Complex A multifactorial disease of CATTLE resulting from complex interactions between environmental factors, host factors, and pathogens. The environmental factors act as stressors adversely affecting the IMMUNE SYSTEM and other host defenses and enhancing transmission of infecting agents.	6.96	7	4
Experimental Lung Inflammation Inflammation of any part, segment or lobe, of the lung parenchyma.	2.17	1	0
Breathing Sounds [description not available]	2.17	1	0
Caprine Diseases [description not available]	2.17	1	0
Pneumonia Infection of the lung often accompanied by inflammation.	7.17	1	0
Respiratory Sounds Noises, normal and abnormal, heard on auscultation over any part of the RESPIRATORY TRACT.	2.17	1	0
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	3.59	1	1
Middle Ear Inflammation [description not available]	3.59	1	1
Otitis Media Inflammation of the MIDDLE EAR including the AUDITORY OSSICLES and the EUSTACHIAN TUBE.	8.59	1	1
Respiratory Tract Diseases Diseases involving the RESPIRATORY SYSTEM.	3.97	2	1
Gait Disorders, Animal [description not available]	3.87	2	1
Bronchial Pneumonia [description not available]	3.5	1	1
Abscess Accumulation of purulent material in tissues, organs, or circumscribed spaces, usually associated with signs of infection.	3.5	1	1
Flavobacteriaceae Infections Infections with bacteria of the family FLAVOBACTERIACEAE.	2.52	2	0
Poultry Diseases Diseases of birds which are raised as a source of meat or eggs for human consumption and are usually found in barnyards, hatcheries, etc. The concept is differentiated from BIRD DISEASES which is for diseases of birds not considered poultry and usually found in zoos, parks, and the wild.	2.52	2	0
Innate Inflammatory Response [description not available]	3.9	2	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	3.9	2	1
Acute-Phase Reaction An early local inflammatory reaction to insult or injury that consists of fever, an increase in inflammatory humoral factors, and an increased synthesis by hepatocytes of a number of proteins or glycoproteins usually found in the plasma.	3.91	2	1
Infections, Paramyxoviridae [description not available]	2.13	1	0
Paramyxoviridae Infections Infections with viruses of the family PARAMYXOVIRIDAE. This includes MORBILLIVIRUS INFECTIONS; RESPIROVIRUS INFECTIONS; PNEUMOVIRUS INFECTIONS; HENIPAVIRUS INFECTIONS; AVULAVIRUS INFECTIONS; and RUBULAVIRUS INFECTIONS.	2.13	1	0
Enzootic Calf Pneumonia [description not available]	4.41	2	2
Eperythrozoonosis [description not available]	3.45	1	1
Bacteroidaceae Infections Infections with bacteria of the family BACTEROIDACEAE.	2.06	1	0
Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.	2.06	1	0

gamithromycin

Description

Cross-References

Synonyms (46)

Research Excerpts

Pharmacokinetics

Bioavailability

Dosage Studied

Roles (2)

Drug Classes (2)

Research

Studies (42)

Study Types

gamithromycin

Description

Cross-References

Synonyms (46)

Research Excerpts

Pharmacokinetics

Bioavailability

Dosage Studied

Roles (2)

Drug Classes (2)

Research

Studies (42)

Study Types

Related Drugs (26)

Related Conditions (44)